Research programme: neuropeptide Y modulators - Lundbeck

Drug Profile

Research programme: neuropeptide Y modulators - Lundbeck

Alternative Names: Lu AA33810

Latest Information Update: 08 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck Research USA
  • Class
  • Mechanism of Action Neuropeptide Y receptor agonists; Neuropeptide Y receptor antagonists; Neuropeptide Y5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Drug abuse; Major depressive disorder; Pain

Most Recent Events

  • 21 Oct 2009 Preclinical pharmacodynamics data in Depression presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 02 Oct 2006 Lead compound from this research programme has entered clinical development
  • 19 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top